Opus Genetics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Opus Genetics, Inc. (IRD) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 0.80% for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-24.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2017-02-24
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2016-03-31 was 0.70%, a 46.15% decline year-over-year.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2015-03-31 was 1.30%, a 13.33% decline year-over-year.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2014-03-31 was 1.50%, a 100.00% increase year-over-year.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2013-03-31 was 0.75%, a 15.73% decline year-over-year.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2016 was 0.80%, a 33.33% decline from fiscal 2015.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2015 was 1.20%, a 20.00% decline from fiscal 2014.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2014 was 1.50%, a 100.00% increase from fiscal 2013.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2013 was 0.75%, a 20.97% increase from fiscal 2012.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month as first filed |
|---|---|---|---|---|---|
| 2016-12-31 | 0.80% 10-K · filed 2017-02-24 | ||||
| 2016-09-30 | 0.80% 10-Q · filed 2016-11-04 | ||||
| 2016-06-30 | 0.60% 10-Q · filed 2016-08-05 | ||||
| 2016-03-31 | 0.70% 10-Q · filed 2016-05-06 | ||||
| 2015-12-31 | 1.20% 10-K · filed 2017-02-24 | ||||
| 2015-09-30 | 1.20% 10-Q · filed 2016-11-04 | ||||
| 2015-06-30 | 1.30% 10-Q · filed 2016-08-05 | ||||
| 2015-03-31 | 1.30% 10-Q · filed 2016-05-06 | ||||
| 2014-12-31 | 1.50% 10-K · filed 2017-02-24 | 1.49% 10-K · filed 2015-03-16 | |||
| 2014-09-30 | 1.49% 10-Q · filed 2015-11-02 | ||||
| 2014-06-30 | 1.50% 10-Q · filed 2015-08-07 | ||||
| 2014-03-31 | 1.50% 10-Q · filed 2015-05-08 | ||||
| 2013-12-31 | 0.75% 10-K · filed 2016-03-14 | ||||
| 2013-09-30 | 0.75% 10-Q · filed 2014-11-12 | ||||
| 2013-06-30 | 0.75% 10-Q · filed 2014-08-13 | ||||
| 2013-03-31 | 0.75% 10-Q · filed 2014-05-14 | ||||
| 2012-12-31 | 0.62% 10-K · filed 2014-03-21 | ||||
| 2012-09-30 | 0.62% 10-Q · filed 2013-11-13 | ||||
| 2012-06-30 | 0.69% 10-Q · filed 2013-08-12 | ||||
| 2012-03-31 | 0.89% 10-Q · filed 2013-05-09 | ||||
| 2011-12-31 | 0.11% 10-K · filed 2013-03-22 | ||||
| 2011-09-30 | 0.11% 10-Q · filed 2012-11-08 | ||||
| 2011-06-30 | 0.18% 10-Q · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |